Loading clinical trials...
Loading clinical trials...
Impact of Antistaphylococcal Penicillins and Cefazolin on the Emergence of Resistance in French Hospitals
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with antistaphylococcal penicillins. Cefazolin has broader spectrum than antistaphylococcal penicillins. The hypothesis of this project is that cefazoline could be responsible for a higher rate of bacterial resistance. The aim is to study the association between the emergence of bacterial resistance and the consumption of cefazolin and antistaphylococcal penicillins.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Lefevre
Nancy, Lorraine, France
Start Date
January 1, 2018
Primary Completion Date
May 1, 2023
Completion Date
June 1, 2023
Last Updated
August 8, 2025
644
ACTUAL participants
Lead Sponsor
Central Hospital, Nancy, France
NCT03226314
NCT01878643
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions